A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free survival and over survival in HER2/neu positive women with locally advanced or metastatic breast cancer who are resistant to trastuzumab and have been pre-treated with a taxane.
Inclusion Criteria:
Exclusion Criteria:
Tucson, Arizona 85724, United States
La Jolla, California 92093-0658, United States
Washington D.C., District of Columbia 20007-2197, United States
Boca Raton, Florida 33248, United States
Atlanta, Georgia 30322, United States
Owning Mills, Maryland 21117,, United States
Las Vegas, Nevada 89109, United States
Summit, New Jersey 07901, United States
Pittsburgh, Pennsylvania 15232, United States
Nashville, Tennessee 37203, United States
Dallas, Texas 75230, United States
Dallas, Texas 75390-8852, United States
San Antonio, Texas 78229, United States
San Antonio, Texas 78258, United States
C A B A, Buenos Aires C1019ABS, Argentina
Caba, Buenos Aires C1050AAK, Argentina
Rio Negro, Viedma 8500, Argentina
East Bentleigh, Victoria 3165, Australia
Saint-Brieuc Cédex, 22015, France
Heraklion Crete, Greece 711 10, Greece
Patra - RIO, GR 265 04, Greece
Bunkyo-ku, Tokyo 113-8431, Japan
Koto, Tokyo 135-8550, Japan
Fatih / Istanbul, 34098, Turkey (Türkiye)
Surrey, England GU2 7XX, United Kingdom